3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
8
Other hematologic neoplasm
4
Breast
4
Plasma cell
3
Other
3
Lymphoid
3
Genitourinary
3
CNS
3
Tumor-Agnostic
1
Thoracic
1
Other solid neoplasm
1
Other neoplasm
1
Myeloid
1
Head & Neck
1
Gynecologic
1
Dermatologic
1
Conditions
Thrombocythemia, Essential
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Myeloproliferative Disorders
1
Motor Activity
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
fludarabine
63
Cyclophosphamide
63
venetoclax
57
Azacitidine
52
fludarabine phosphate
50
Specimen Handling
44
Whole-Body Irradiation
40
ruxolitinib
37
Mycophenolic Acid
37
Tacrolimus
35
Melphalan
32
Busulfan
32
Biopsy
32
Cytarabine
31
Stem Cell Transplantation
27
Decitabine
27
Granulocyte Colony-Stimulating Factor
21
asciminib
19
decitabine and cedazuridine drug combination
18
Sirolimus
18
Peripheral Blood Stem Cell Transplantation
18
Injections
18
Thiotepa
17
Filgrastim
17
nilotinib
15
X-Rays
14
Methotrexate
14
Cyclosporine
14
Imatinib Mesylate
13
Magnetic Resonance Spectroscopy
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Resistance Training
×
Myeloid
×
1 year
×
Clear all
NCT07518940
2026-04-09
ENERGIA
University of Turin, Italy
Phase NA
Not yet recruiting
25 enrolled